Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
about
Strategies for modern biomarker and drug development in oncology.Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective studyPrognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Sorafenib: 10 years after the first pivotal trial.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.SCUBE1: a promising biomarker in renal cell cancerRenal cell carcinoma: An update for the practicing urologist.Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
P2860
Q30590270-DAA05F03-43D9-4851-9FEF-D2FC54BC04BEQ35451764-20528830-7C71-428C-AEBD-94784BDF4082Q35540063-02A8C621-9223-4687-BDE5-D652DF45EC75Q35811446-A7D1361F-8180-4814-A08E-65DF2A9DF9CCQ36893510-5447ACB5-BC9E-4C70-B756-098054E6646FQ38116001-278D14A1-11DF-4AAB-A39F-D23369452F1DQ38196855-54B4045F-35C1-42A6-9AE2-7341BEF46786Q38544841-06039163-120B-4E03-A3C4-19F4BB1CC735Q38546217-98A86A08-15C1-4A31-BFC9-3F6EA645DE64Q38947146-EDFFD8B0-D8A6-44A4-92AA-957D2FECD68AQ39097822-6CF4CAE8-C690-4898-9118-F63CAB1EDEDCQ41412069-994B8569-EE77-421B-8675-A66BF3B62A20Q53649433-60376C5C-E643-42A4-82F6-EB681104ABD5Q58585071-87C5E0BF-8A6F-46E7-B38B-F159B3184F1F
P2860
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@ast
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@en
type
label
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@ast
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@en
prefLabel
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@ast
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@en
P2093
P2860
P1433
P1476
Carbonic anhydrase IX as a pot ...... bal evaluation trial (TARGET).
@en
P2093
Angela Q Qu
Jaromir Pastorek
Michael B Atkins
Sabina Signoretti
Suchun Cheng
Toni K Choueiri
P2860
P304
P356
10.1016/J.UROLONC.2012.07.004
P577
2012-11-07T00:00:00Z